EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC-ND 4.0

The role of antifactor Xa monitoring in the dosing and administration of low-molecular-weight heparins in pregnancy: a systematic review and meta-analysis

Rizwana Ashraf, Dina Mohamed, Shahab Sayfi, James M Bowen, Irving Steinberg, Nadine Shehata, Michelle Hwang, Rohan D'Souza

Journal of Thrombosis and Haemostasis · 2026-11 · 24 (11) · 4012-4026

DOI: 10.1016/j.jtha.2026.08.017 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-11. Verfasst von Rizwana Ashraf und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics & Gynaecology, McMaster University, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence and Impact, F…. Hauptthemen laut MEDLINE: Heparin, Low-Molecular-Weight, Venous Thromboembolism, Factor Xa Inhibitors, Anticoagulants. Die Arbeit nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Low-molecular-weight heparins (LMWHs) are widely used in pregnancy for prevention and treatment of venous thromboembolism (VTE) and in individuals with mechanical heart valves (MHVs). OBJECTIVES: Our aim was to determine the risk of thromboembolic complications (TECs) and major bleeding with weight-based, fixed, and anti-Xa-monitored dosing of LMWHs during pregnancy. METHODS: We conducted a systematic review and searched 6 databases for articles published before August 2024 that reported on LMWH dosing and monitoring during pregnancy. We calculated event rates and 95% confidence intervals (95% CIs) for maternal death, TECs, and major bleeding using a random-effects meta-analysis. We assessed risk of bias using the Quality In Prognosis Studies tool and evaluated the certainty of evidence (CoE) using the Grading of Recommendations, Assessment, Development, and Evaluation approach. RESULTS: We identified 5007 studies, of which 94 (53 case series, 30 cohort studies, and 11 randomized trials) were eligible. For thromboprophylaxis and VTE treatment, fixed, weight-based, and anti-Xa-monitored LMWH doses had overlapping pooled event rates and 95% CIs for TECs and major bleeding. For MHVs, the risk of maternal death, TECs, and major bleeding was 2.7% (95% CI, 0.3%-6.5%), 7.9% (95% CI, 2.8%-14.6%), and 8.4% (95% CI, 2.0%-17.2%), respectively with overlapping pooled single-arm event rates and 95% CIs across different anti-Xa-monitored LMWH dosing regimens. The CoE for all estimates was low to very low, mainly due to imprecision, risk of bias, and publication bias. CONCLUSION: Pooled single-arm event rates and 95% CIs for the main outcomes overlapped across LMWH dosing regimens currently used in pregnancy for thromboprophylaxis, VTE treatment, and anticoagulation in individuals with MHVs. These findings should be interpreted in light of small sample sizes, wide 95% CIs, and low CoE; and not as evidence of comparable effectiveness or safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heparin, Low-Molecular-WeightVenous ThromboembolismFactor Xa InhibitorsAnticoagulantsPregnancy Complications, CardiovascularDrug MonitoringHumansFemalePregnancyHemorrhageRisk FactorsTreatment OutcomeRisk AssessmentHeart Valve ProsthesisBlood Coagulation

Stichwörter der Autor:innen

anticoagulantsheart valve prosthesislow-molecular-weight heparinsthrombosisvenous thromboembolism

Substanzen

Heparin, Low-Molecular-WeightFactor Xa InhibitorsAnticoagulants

Autor:innen und Institutionen

  • Department of Obstetrics & Gynaecology, McMaster University, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Can…
  • Department of Obstetrics & Gynaecology, McGill University, Montreal, Québec, Canada.
  • Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada; Program for Health System and Technology Evaluation, Ted Rogers Centre for Heart Re…
  • Department of Pediatrics, University of Southern California (USC) Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, Keck School of Medicine of USC, University of Southern California, Los Angeles, California…
  • Division of Haematology, Departments of Medicine and Laboratory Medicine and Pathobiology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Library & Knowledge Services, Trillium Health Partners, Toronto, Ontario, Canada.

Zitieren

APA

Ashraf, R., Mohamed, D., Sayfi, S., Bowen, J. M., Steinberg, I., Shehata, N., Hwang, M., & D'Souza, R. (2026). The role of antifactor Xa monitoring in the dosing and administration of low-molecular-weight heparins in pregnancy: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 24(11), 4012-4026. https://doi.org/10.1016/j.jtha.2026.08.017

Vancouver

Ashraf R, Mohamed D, Sayfi S, Bowen JM, Steinberg I, Shehata N, et al. The role of antifactor Xa monitoring in the dosing and administration of low-molecular-weight heparins in pregnancy: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis. 2026;24(11):4012-4026. doi:10.1016/j.jtha.2026.08.017

BibTeX
@article{Ashraf2026,
  author = {Ashraf, Rizwana and Mohamed, Dina and Sayfi, Shahab and Bowen, James M and Steinberg, Irving and Shehata, Nadine and Hwang, Michelle and D'Souza, Rohan},
  title = {The role of antifactor Xa monitoring in the dosing and administration of low-molecular-weight heparins in pregnancy: a systematic review and meta-analysis},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  volume = {24},
  number = {11},
  pages = {4012--4026},
  doi = {10.1016/j.jtha.2026.08.017}
}
Kostenlos starten →